ENTO (ENTO) Stock Analysis

ENTO (ENTO) Healthcare & Pipeline Overview

Entero Therapeutics, Inc. (ENTO) is a clinical-stage biopharmaceutical company focusing on targeted, non-systemic therapies for gastrointestinal diseases. Their pipeline features latiglutenase for celiac disease and niclosamide for inflammatory bowel diseases, positioning them in a competitive market seeking innovative GI treatments.

What Is the Investment Thesis for ENTO?

Entero Therapeutics, Inc. presents a high-risk, high-reward investment profile typical of clinical-stage biopharmaceutical companies. The company's focus on non-systemic GI therapies addresses a significant market need. Key value drivers include successful clinical trial outcomes for latiglutenase and niclosamide. The company's small market capitalization of $13.6M reflects its early stage and inherent risks. Growth catalysts include potential partnerships, FDA approvals, and positive clinical data releases. However, the company's negative profit margin of -18078.3% and gross margin of -3398.9% highlight its dependence on future funding and successful commercialization. Investors should carefully consider the regulatory hurdles, clinical trial risks, and competitive landscape.

Based on FMP financials and quantitative analysis

ENTO Key Highlights

Market capitalization of $13.6M indicates a small-cap, high-risk investment.

• Profit margin of -18078.3% reflects significant ongoing research and development expenses.
• Gross margin of -3398.9% indicates that the cost of revenue exceeds revenue, typical for a clinical-stage biopharmaceutical company.
• Beta of 1.19 suggests the stock is slightly more volatile than the market.
• The company has no dividend yield, consistent with its focus on reinvesting earnings into research and development.

Who Are ENTO's Competitors?

ENTO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ENTO's Key Strengths?

Pipeline of targeted therapies for GI diseases.

• Focus on non-systemic treatments to reduce side effects.
• Proprietary drug formulations and technologies.
• Experienced management team in drug development.

What Are ENTO's Weaknesses?

Limited financial resources as a small-cap company.

• Dependence on successful clinical trial outcomes.
• High risk of regulatory setbacks.
• Negative profit and gross margins.

What Could Drive ENTO Stock Higher?

Clinical trial results for latiglutenase in celiac disease.

• Clinical trial results for niclosamide in inflammatory bowel diseases.
• Potential partnerships with larger pharmaceutical companies.
• Advancement of CypCel disease management tool.
• Regulatory interactions with the FDA.

What Are the Key Risks for ENTO?

Financial-distress signal — its Altman Z-Score of -9.69 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-18.7%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 3 of the last 4 reported quarters.
• Failure to obtain positive clinical trial results.
• Regulatory setbacks and delays.
• Competition from established pharmaceutical companies.
• Limited financial resources and dependence on future funding.
• Patent expirations and generic competition.

What Are the Growth Opportunities for ENTO?

• Latiglutenase for Celiac Disease: Latiglutenase represents a significant growth opportunity for Entero Therapeutics. Latiglutenase, designed to break down gluten into non-immunogenic peptides, could capture a substantial share of this market if clinical trials are successful and regulatory approval is obtained. The timeline for potential commercialization depends on the progress of clinical trials, with potential launch in 3-5 years pending positive results.
• Niclosamide for Inflammatory Bowel Diseases: Niclosamide, with its anti-inflammatory properties, offers another growth avenue for Entero Therapeutics in the inflammatory bowel disease (IBD) market. The IBD market, including ulcerative colitis and Crohn's disease, is expected to grow significantly due to increasing prevalence and unmet medical needs. If clinical trials demonstrate efficacy and safety, niclosamide could become a valuable treatment option, potentially launching in 4-6 years. Success hinges on positive clinical data and regulatory approval.
• Adrulipase for Exocrine Pancreatic Insufficiency: Adrulipase, a recombinant lipase enzyme, targets exocrine pancreatic insufficiency (EPI), a condition characterized by the inability to properly digest fats. The EPI market is driven by an aging population and increasing awareness of the condition. Successful development and commercialization of adrulipase could provide a significant revenue stream for Entero Therapeutics, with potential launch in 3-5 years contingent on clinical trial outcomes and regulatory approvals.
• CypCel Disease Management Tool: The CypCel disease management tool for monitoring intestinal health in celiac disease patients represents a unique growth opportunity. As a diagnostic and monitoring tool, CypCel could generate recurring revenue and enhance patient management. The market for celiac disease monitoring tools is growing, driven by the need for better diagnostic and management solutions. Commercialization of CypCel could occur within 2-3 years, pending successful development and validation.
• Partnerships and Licensing Agreements: Entero Therapeutics can pursue growth through strategic partnerships and licensing agreements with larger pharmaceutical companies. Collaborations can provide financial resources, development expertise, and commercialization capabilities. Licensing agreements for specific drug candidates or technologies can generate upfront payments, milestone payments, and royalties. Successful partnerships can accelerate the development and commercialization of Entero Therapeutics' pipeline and expand its market reach. The timeline for securing partnerships is ongoing, with potential deals occurring in the next 1-3 years.

What Are ENTO's Competitive Advantages?

• Proprietary drug formulations and technologies.
• Patent protection for key drug candidates.
• Clinical data supporting drug efficacy and safety.
• Expertise in gastrointestinal disease research and development.

What Does ENTO Do?

Entero Therapeutics, Inc., formerly known as First Wave BioPharma, Inc. and originally as AzurRx BioPharma, Inc., is a clinical-stage biopharmaceutical company established in 2014 and headquartered in Boca Raton, Florida. The company is dedicated to the research and development of targeted and non-systemic therapies aimed at treating gastrointestinal diseases. Their product pipeline includes several drug candidates, such as latiglutenase, an oral biotherapeutic designed to break down gluten into non-immunogenic peptides for celiac disease patients. Another key product is adrulipase, a recombinant lipase enzyme intended to aid in the digestion of fats and nutrients. Additionally, they are developing capeserod, a selective 5-HT4 receptor partial agonist for gastroparesis, and niclosamide, an oral small molecule with anti-inflammatory properties for inflammatory bowel diseases like ulcerative colitis and Crohn's disease. Entero Therapeutics is also working on CypCel, a disease management tool to monitor the intestinal health of recovering celiac disease patients. The company aims to provide innovative solutions for unmet needs in the treatment of gastrointestinal disorders.

What Products and Services Does ENTO Offer?

• Develop targeted therapies for gastrointestinal diseases.
• Research non-systemic treatments to minimize side effects.
• Focus on unmet needs in celiac disease, IBD, and gastroparesis.
• Develop oral biotherapeutics and small molecule drugs.
• Create disease management tools for monitoring patient health.
• Conduct clinical trials to evaluate drug efficacy and safety.
• Seek regulatory approvals from the FDA for commercialization.

How Does ENTO Make Money?

• Develop and license pharmaceutical products.
• Conduct clinical trials to prove efficacy.
• Seek FDA approval for commercialization.
• Potentially partner with larger pharmaceutical companies for distribution.

What Industry Does ENTO Operate In?

Entero Therapeutics, Inc. operates within the competitive biotechnology industry, which is characterized by high R&D spending, lengthy regulatory approval processes, and significant market potential. The company focuses on gastrointestinal diseases, a market driven by increasing prevalence of conditions like celiac disease and inflammatory bowel diseases. According to market research reports, the global gastrointestinal drugs market is expected to grow, driven by the development of novel therapies. Entero Therapeutics competes with both large pharmaceutical companies and smaller biotech firms in developing innovative treatments. Success in this industry depends on clinical trial outcomes, regulatory approvals, and effective commercialization strategies.

Who Are ENTO's Key Customers?

• Patients with gastrointestinal diseases (celiac disease, IBD, gastroparesis).
• Healthcare providers (gastroenterologists, primary care physicians).
• Hospitals and clinics.
• Pharmacies.

The most recent 2 insider filings for ENTO break down as 1 sales and 1 purchases. On net that is roughly 24K shares acquired (about $1K) — insiders putting money in tends to read as conviction.

ENTO has missed Wall Street's EPS estimate in 3 of its last 4 reported quarters — a mixed record worth weighing. Reported results have landed about 151.5% below estimates on average.

ENTO's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -9.69 places it in the distress zone, a signal of elevated financial risk.

Return on equity for ENTO stands at -18.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -18.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -42.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.16 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -41.6%, the inverse of the P/E and a quick read on earnings relative to price.

ENTO (ENTO) Valuation Context

Valued at $13.6M, ENTO is classified as a micro-cap stock.

ENTO Revenue & Earnings Trend

In Q2 FY2026, ENTO generated $86K in top-line revenue, marking a sequential increase of 124.8%. The company recorded a net loss of $221K, with diluted EPS of $-0.03. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, ENTO averaged $-0.86 in diluted EPS.

Company Profile

ENTO operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Boca Raton, US. The company is led by CEO Jason David Sawyer. ENTO has traded publicly since 2016.

ENTO Financials

ENTO Latest News

ENTO Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources